0.9369
Xilio Therapeutics Inc stock is traded at $0.9369, with a volume of 559.69K.
It is up +6.60% in the last 24 hours and up +19.32% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.8789
Open:
$0.88
24h Volume:
559.69K
Relative Volume:
0.56
Market Cap:
$48.51M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.3165
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+12.20%
1M Performance:
+19.32%
6M Performance:
-7.24%
1Y Performance:
+2.14%
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XLO
Xilio Therapeutics Inc
|
0.9369 | 46.51M | 0 | -81.22M | -74.41M | -2.96 |
![]()
ONC
Beigene Ltd Adr
|
240.41 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
Jan-10-22 | Initiated | H.C. Wainwright | Buy |
Nov-16-21 | Initiated | Cowen | Outperform |
Nov-16-21 | Initiated | Guggenheim | Buy |
Nov-16-21 | Initiated | Morgan Stanley | Overweight |
Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World
50,086 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Raymond James Financial Inc. - Defense World
Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart at ASCO 2025, Advancing Tumor-Activated Immuno-Oncology Pipeline - Nasdaq
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Renaissance Technologies LLC Boosts Holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Geode Capital Management LLC Acquires 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan
Xilio’s Stacey Davis recruited by Enara - The Pharma Letter
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - The Manila Times
Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting - Nasdaq
Phase 2 Trial Results: Novel Tumor-Activated Therapy Shows Promise in Hard-to-Treat Colorectal Cancer - Stock Titan
Raymond James Financial Inc. Takes Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - The AM Reporter
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World
Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World
Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World
Deals In Depth: February 2025 - insights.citeline.com
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks
Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia
Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com
Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India
Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India
Xilio Therapeutics, Inc. SEC 10-K Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView
Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq
Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xilio Therapeutics Inc Stock (XLO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):